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Abstract
Science is beginning to understand how genetic variation and epigenetic events alter requirements
for, and responses to, nutrients (nutrigenomics). At the same time, methods for profiling almost all
of the products of metabolism in a single sample of blood or urine are being developed
(metabolomics). Relations between diet and nutrigenomic and metabolomic profiles and between
those profiles and health have become important components of research that could change clinical
practice in nutrition. Most nutrition studies assume that all persons have average dietary
requirements, and the studies often do not plan for a large subset of subjects who differ in
requirements for a nutrient. Large variances in responses that occur when such a population exists
can result in statistical analyses that argue for a null effect. If nutrition studies could better identify
responders and differentiate them from nonresponders on the basis of nutrigenomic or metabolomic
profiles, the sensitivity to detect differences between groups could be greatly increased, and the
resulting dietary recommendations could be appropriately targeted. It is not certain that nutrition will
be the clinical specialty primarily responsible for nutrigenomics or metabolomics, because other
disciplines currently dominate the development of portions of these fields. However, nutrition
scientists' depth of understanding of human metabolism can be used to establish a role in the research
and clinical programs that will arise from nutrigenomic and metabolomic profiling. Investments made
today in training programs and in research methods could ensure a new foundation for clinical
nutrition in the future.
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INTRODUCTION
Nutrigenomics (the study of the bidirectional interactions between genes and diet) and
metabolomics (the integrated study of the many small molecules produced by metabolism) are
rapidly developing new bodies of knowledge that will change future research and practice in
human nutrition. Just as the published human genome is an average representation of genes in
humans, there is a human metabolome that is an average representation of metabolic potential
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for humans. However, there is significant variation from the average in both genome and
metabolome in any given individual. Nutrigenomic and metabolomic profiling will help
identify mechanisms that underlie individual variations in dietary requirements as well as in
the capacity to respond to food-based interventions.
Although nutrition clinicians eventually may be able to provide personalized nutrition
recommendations, they are most likely, in the immediate future, to use this knowledge to
improve dietary recommendations for populations. Currently, estimated average requirements
are used to set dietary reference intakes, because scientists cannot adequately identify subsets
of the population that differ in their requirements for a nutrient. Recommended intakes must
exceed the actual required intake for most of the population to ensure that those persons with
the highest requirement ingest adequate amounts of the nutrient. As a result, dietary reference
intakes often are set so high that diet guidelines suggest an almost unattainable intake of some
foods. Once it is possible to identify common subgroups that differ in nutrient requirements
by using nutrigenomic and metabolomic profiling, interventions can be targeted and
recommendations can be made that avoid suggesting that the entire population needs to use
almost all discretionary calories to meet nutrient requirements. Similarly, nutrigenomic and
metabolomic profiling can enhance nutrition epidemiology and nutrition intervention research.
When a large variance exists in response to a nutrient, statistical analyses often argue for a null
effect. If responders could be differentiated from nonresponders on the basis of nutrigenomic
and metabolomic profiles, this statistical noise could be eliminated and the sensitivity of
nutrition research greatly increased.
It is apparent that a niche will exist for health professionals who can effectively place the new
information generated by nutrigenomic and metabolomic profiling into a context that enables
integration, interpretation, and, subsequently, individualized dietary recommendations. Thus,
the field of nutrition would benefit by establishing itself as the predominant discipline using
this knowledge in clinical and public health practice.
Concrete examples can help nutrition scientists to envision how such new knowledge will
change current practice. In this report, several aspects of nutrigenomic and metabolomic
profiling are considered, and concrete examples from current research are provided that
foreshadow how nutrition science and practice can make use of such data.
Nutrient-gene interactions
There are 3 major conceptual groupings for thinking about nutrient-gene interactions: 1) direct
interactions: nutrients, sometimes after interacting with a receptor, behave as transcription
factors that can bind to DNA and acutely induce gene expression; 2) epigenetic interactions:
nutrients can alter the structure of DNA (or of histone proteins in chromatin) so that gene
expression is chronically altered; and 3) genetic variations: common genetic variations [single-
nucleotide polymorphisms (SNPs)] can alter the expression or functionality of genes. All of
these mechanisms can result in altered metabolism of and altered dietary requirements for
nutrients.
Acute effects of nutrients on gene transcription
There are many examples of nutrients acting as transcription factors that modify gene
expression. Vitamin A, or rather retinoid derivatives of vitamin A, interact with retinoic acid
receptor proteins, and these complexes activate or repress transcription when they bind to
motifs (eg, retinoic acid response elements) in gene promoter regions (1). Dietary fatty acids
can interact with peroxisome proliferator–activated receptors, which then bind to DNA and
modify gene expression (2). Other examples of nutrient-response element interactions that
modify gene expression include the interactions of vitamin D with the vitamin D receptor,
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calcium with calcineurin, and zinc with metal-responsive transcription factor 1 (3). All of these
examples involve a nutrient that acts as a short-term signal to acutely alter gene transcription;
this effect usually stops if the exposure to the nutrient is removed. Because such examples are
familiar to most nutrition scientists, they are not a focus of this discussion.
Epigenetics and nutrition
It is only relatively recently that science began to understand epigenetic mechanisms for
sustained effects of nutrients on gene expression. These sustained effects are mediated by
methylation of DNA or by methylation, acetylation, or biotinylation of his-tones, or by both
functions (4). Such epigenetic modifications can result in changes in gene expression that can
last throughout a person's life and can even persist across generations.
DNA methylation usually occurs at cytosine bases that are followed by a guanosine (5′-CpG-3′
islands) (5), and it influences gene transcription and genomic stability (6–8). In mammals, 60
−90% of 5′-CpG-3′ islands are methylated (9). When this modification occurs in gene promoter
regions, expression is altered (10). Increased methylation is usually associated with gene
silencing or reduced gene expression (9), because methylated 5′-CpG-3′ islands attract capping
proteins that hinder access to the gene for the transcription factors that normally induce gene
expression (Figure 1) (11). There are some exceptions, in which gene methylation prevents the
binding of inhibitory factors that results in derepression of the gene, but that is uncommon.
Once 5′-CpG-3′ islands in genes are methylated, the methylation is reproduced every time the
gene is copied. Thus, the effects of methylation can persist.
DNA is wrapped on proteins (histones) that, when packed tightly together, prevent access to
the promoter sequences of genes. Methylation and acetylation [and perhaps biotinylation
(12,13)] of these histones can uncoil them, creating channels through which transcription
factors can pass and activate gene promoters. These changes in histones are often triggered
subsequent to methylation of 5′-CpG-3′ islands in gene DNA (4).
Changes in the dietary availability of methyl groups can induce stable changes in gene
methylation, altering gene expression and the resulting phenotype (14,15). For example,
feeding pregnant pseudoagouti Avy/a mouse dams a methyl-supplemented diet altered the
epigenetic regulation of agouti gene expression in their offspring, as indicated by increased
agouti or black mottling of their coats (14,16); hair color was permanently altered because the
pregnant mother ate more or less of a nutrient that changed the methylation of DNA in the
fetus. In a similar study, maternal dietary intake of methyl groups influenced methylation of
the Axin Fused gene and determined whether offspring had permanently kinked tails (17).
Feeding pregnant mice or rats more or less choline (a methyl donor) influenced the rate at
which brain progenitor cells proliferated in the fetus; it also influenced the rates of apoptosis
(cell suicide) in these cells (18,19). Decreased choline availability to pregnant dams was
associated with changes in DNA methylation in fetal brains that were specific to some CpG
islands, and even to specific CpG sites, within genes that regulate cell cycling (20,21). Fetuses
of dams fed a low-choline diet during days 11−17 of gestation had half as much neural
progenitor cell proliferation and twice as much progenitor cell apoptosis in the hippocampus
(memory center) as did fetuses from mothers fed choline-adequate diets (19,22), and the former
group of fetuses also had less visuospatial and auditory memory than did those of the latter
group (23). The feeding of greater amounts of choline (≈4 times dietary levels) to pregnant
dams enhanced visuospatial and auditory memory in their offspring by ≤30% in the adult
animals (23–29). Indeed, adult rodents lose memory function as they age, and offspring
exposed to extra choline in utero did not show this “senility” (26,28).
Epigenetic effects of nutritional variation are not restricted to fetal life, nor are they seen only
in the rodent. Investigators found longer survival and a 75% lower risk of diabetes mellitus in
Zeisel Page 3













humans whose paternal grandfathers experienced food scarcity during the slow growth period
just before puberty than in those whose paternal grandfathers did not (30–32). Pembrey (32)
effectively argued that these effects of nutrition must occur via epigenetic imprinting of
paternal genes and pointed out that the slow growth period before puberty occurs when the
first viable pools of spermatocytes emerge and when reprogramming of DNA methylation
imprinting begins. In a similar fashion, epi-genetic events can modulate carcinogenesis in the
adult; for example, a number of single-copy genes whose expression is restricted to the testes
(32) in adults become hypomethylated and are reexpressed in some cancers (33).
Technology will soon make it practical to catalog epigenetic changes in many genes at one
time (34). Because a significant portion of human genes are regulated by methylation, many
more examples should accrue of diet-related changes in gene methylation.
Genetic variation can influence dietary requirements
Although humans share the same genes, there are many individual variations in the codon
sequences for these genes; in total, >10 million SNPs exist that occur in >1% of the population
(35). Some common SNPs occur in 5% to >50% of the population. Most humans are
heterozygous for ≥50 000 SNPs across their genes (36). Some fraction of these SNPs results
either in alteration of gene expression or in changes in the gene product such that protein
structure and function are altered. Mastering the ways in which millions of SNPs may influence
nutrient requirements is daunting, but recent advances make this effort more practical. Even
though the costs of genotyping have dropped markedly, the number of markers now available
per gene makes the genotyping of all markers expensive. Because of this, scientists need to
select for genotyping a set of markers that would eliminate the necessity of measuring all SNPs.
Within short regions (ie, ≤500 kb) of a gene, it is possible to find combinations of linked SNPs
that are found in multiple unrelated persons (haplotype blocks). These SNPs stay linked to one
another and are inherited over many generations. An international scientific consortium has
recently characterized patterns of SNP linkage in haplotype blocks (36,37). The identification
of a few alleles of a haplotype block can unambiguously identify all other polymorphic sites
in its region within a group of persons of similar race and ethnicity, thereby making SNP
analysis practical for the nutrition scientist or clinician.
A number of relatively common SNPs are known to influence nutrient requirements. For
example, the enzyme 5,10-methylenetetrahydrofolate reductase (MTHFR) is involved in folate
metabolism. The MTHFR gene has a common SNP (C677T allele) that results in reduced
enzymatic activity, and homozygous persons have elevated plasma homocysteine
concentrations unless they ingest high amounts of folate (38). This SNP occurs in 15−30% of
the population.
Another example comes from work on SNPs that modify the risk of developing organ
dysfunction or damage when humans are fed diets low in choline (39–42). Some persons
developed fatty liver and liver and muscle damage, whereas others did not. Premenopausal
women who were carriers of a very common SNP (MTHFD1-G1958A) were >15 times as
likely as noncarriers to develop signs of choline deficiency on a low-choline diet (43). It is of
interest that the risk of having a child with a neural tube defect increased in mothers with this
SNP (44), and that, compared with women eating diets in the highest quartile for choline intake,
women eating diets in the lowest quartile had 4 times the risk of having a baby with a neural
tube defect (45). It would be interesting to determine whether those with the greatest risk have
the G1958A SNP in MTHFD1.
The PEMT gene encodes for a protein responsible for endogenous formation of choline in the
liver (46), and it is induced by estrogen (47). In studies of organ dysfunction after choline
deficiency in humans, an SNP in the promoter region of the PEMT gene (rs12325817) was
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associated with greatly increased susceptibility to choline deficiency in women but not in men
(42). The frequency of this variant allele was 0.74 (this common allele is called the “variant”
one because wild type was determined by the codon present in lower mammals). Studies are
underway to identify other genetic differences that contribute to individual variability in dietary
requirements for choline.
Although all of the above examples of genetic variation that change nutrient requirements
involved one-carbon metabolism, SNPs have been identified that affect other metabolic
pathways. For example, an SNP in the SREBP gene affects fructose-induced hepatic
lipogenesis (48). The gene for peroxisome proliferator–activated receptor-α has an SNP that
has been associated with alterations in total cholesterol, LDL-cholesterol, and apolipoprotein
B concentrations (49), and this SNP altered the response to the dietary intake of n–6
polyunsaturated fatty acid. In persons with the variant allele, increased n–6 polyunsaturated
fatty acid intake was associated with a marked reduction in triacylglycerol concentration
(49).
A database of functionally important SNPs would make it possible for a nutrition specialist—
one who has an understanding of the effects of such changes on metabolism and nutrient
requirements—to use SNP profiling to make practical recommendations as part of clinical
practice (eg, a recommendation of higher dietary choline intake during pregnancy in women
with SNPs that alter PEMT expression).
The challenges in applying nutrigenomic data to nutrition
The above examples show that it is now possible to think about how individual gene SNPs
alter nutrient requirements and about how methylation of a particular gene is influenced by
nutrition. Obviously, these concepts are just a simplified version of what nutrition science will
have to deal with in the future. It is possible to detect tens of thousands of SNPs and at least
the same number of epigenetic changes in genes. It is likely that these changes interact with
each other in a complex way. Whereas their sequences are known, the functions of many of
the genes identified in the human genome are unknown, as are the functional consequences of
most of the identified SNPs in humans. Even when these functions are known, in order to
integrate any differences and predict their effects on body function, scientists will need to
overlay each of these changes onto the familiar map of metabolic pathways. Then algorithms
will have to be developed that allow the identification of patterns in the measured changes—
eg, groupings of related genes that regulate metabolic pathways and then groupings of related
metabolic pathways. Although these are daunting tasks, managing gene expression data also
appeared difficult 10 y ago, but current off-the-shelf bioinformatics software makes such data
accessible to the interested scientist. In a short time, software will make gene expression data
accessible to the clinician. Only the magnitude of the complexity involved in nutrigenomics
makes it harder to develop the bioinformatics tools needed for these data to be accessible;
conceptually, there is little in the way.
Nutrition and metabolomics
The integrated study of the many small molecules formed by metabolism has always been a
primary domain for nutrition science. For this reason, most nutrition scientists immediately
grasp the advantages gained from being able to measure many metabolites rather than a few.
In the past, analytic limitations made life relatively simple, and the nutritional biochemist dealt
with perhaps a half-dozen metabolites, developed an integrated theory for how they related to
each other, and predicted the effects on cell function or disease. The complexity created by
technology that permits the analysis of thousands of metabolites simultaneously spawned the
new field of metabolomics.
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The unique challenges of applying metabolomics methods to nutrition science have been
reviewed elsewhere (50). A blood, saliva, or urine sample generates thousands of peaks on a
mass spectrometer or nuclear magnetic resonance analysis. A standard chart of human
metabolism lists ≈800 molecules, and available databases suggest that there will be 2000
molecules in the human metabolome (with thousands more if bacterial metabolites are
included). Because the new instruments are so sensitive, it is likely that previously unsuspected
molecules will be detected in human biofluids, which will lead to a reconsideration of the
understanding of metabolism. The field is limited by the fact that the chemical identity of these
peaks is not yet known, by methodologic problems in quantitation of peaks, and by a lack of
sufficiently refined bioinformatics tools that permit analyses in a metabolic pathways context.
Many investigators use principal components analysis to detect relations between a given
intervention and a measured metabolome. Principal components analysis reduces
multidimensional datasets to lower dimensions for analysis by using the characteristics of the
dataset that contribute most to its variance. Investigators can then recognize patterns of change,
even though they may not be certain of the identity of the peaks that contribute to this pattern.
For example, a patient with renal disease may have a pattern of peaks in a chromatogram that
is characteristically different from that of a healthy person. To move beyond principal
components analyses, scientists need to systematically catalog the chemical identity of the
unknown peaks detected in the human metabolome. The peaks for all the known metabolites
of nutrients are mixed in with peaks derived from the many non-nutrient molecules that are
absorbed, metabolized, passed through the blood, and secreted in both urine and saliva. The
large-bowel microflora produce many or most of these peaks that constitute the metabolome
of biofluids in humans, and this contribution presents an additional challenge, because our
understanding of microflora metabolism is not nearly as complete as our understanding of
human metabolism. Eventually, nutrition scientists will use such measures of microflora
metabolism to develop a better understanding of the role of gut microflora in human nutrition.
For example, metabolomic analyses showed that the altered availability of choline caused by
metabolism by gut microflora was associated with fatty liver in insulin-resistant mice (51).
In addition to peak identification, there is a need to verify that peak areas are proportional to
concentrations for each metabolite. In some methods, molecules in neighboring peaks can
modify detector response, thereby altering the relation of area to concentration. In addition,
scientists must establish that data generated from total-metabolome assay methods correlate
with data generated by using gold-standard single metabolite assays. Multidisciplinary research
teams are currently working to validate methods and catalog the human metabolome, and it is
reasonable to expect that this will be accomplished within 5 y. The commercial sector has
already developed platforms for SNP assessment that are readily available for a reasonable
price. It appears that epigenetic assessment availability is only a year or so away. Metabolomic
methodology is being developed and is currently at the experimental stage in university,
industry, and government laboratories. Notable among these efforts are the European Union–
funded Network of Excellence (NuGo) and the Human Metabolome Project funded by Genome
Canada. These efforts can be augmented if the major academic units with nutrition expertise
aggregate their intellectual mass to work together to create usable analytic methods.
Making nutrigenomics and metabolomics accessible to the nutrition clinician
At present, the data-mining and analytic software available is divided into areas according to
the kind of data being analyzed. Gene expression data are mined with different software than
are epigenetic data, and metabolomic data are analyzed in completely different ways. Each
piece of software requires training in its use, and each has its special eccentricities. Eventually,
a suite of software needs to be developed that can manage these data in an integrated platform.
Changes in genes, gene methylation, and metabolism are all related and can be understood only
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when these disparate elements are brought together. A reasonable first step would be to adopt
the common metabolic map that nutritional and biochemical science has developed over the
past 6 decades. After statistical analyses (eg, significance, variance, and false discovery filters),
data would be expressed in relation to the specific reactions in the metabolic pathways (Figure
2). For example, in a study in which data on genes and metabolites of glucose metabolism are
collected, one would use existing information about metabolism to group the observed changes
and create a graphic presentation that is immediately understandable. Good software could
permit examination of the data by zooming from a micro level (pathways of gluconeogenesis)
to the level of glucose metabolism as a whole or to the even larger scale of liver or whole-body
metabolism. Eventually, computer algorithms would identify patterns in these changes and
help the user to develop hypotheses that explain the observation and to make recommendations
for diet change. This process is much more complex than but not very different conceptually
from what a clinician does now: measures glucose concentration and insulin activity, uses an
algorithm to decide if insulin insensitivity is present, and then intervenes as appropriate.
The tools currently available to nutritionists for analysis of metabolomic data are sparse,
difficult to use, or beyond the financial means of individual scientists. However, given the
demand for such tools, it is reasonable to expect that they will be refined and will become
available within 5 y and that they will make metabolomic and nutrigenomic data accessible
first to nutrition scientists and then to nutrition clinicians.
Planning for the future
Although the analytic and informatics capacities to effectively use metabolomics and
nutrigenomics are a few years away, nutrition scientist and educators need to act soon to set
the stage appropriately. A decade from now, science will have identified complex associations
between diet and the expression of thousands of genes with simultaneous changes in thousands
of metabolites. The integration of nutrigenomics and metabolomics with the metabolic map
will be incredibly complex, but there are manageable pieces of this effort that could be
addressed by those who have spent a lifetime developing expertise in nutrition and metabolism.
The ultimate challenge will be in making sense of what will be a huge, perhaps overwhelming
amount of data so that nutrition clinicians can use those data to make practical
recommendations. On a smaller scale, nutrition scientists, with their integrative knowledge of
metabolism, do this already. These scientists should assist with the development of informatics
tools to facilitate the interpretation of exponentially more complex sets of data. The analytic
and informatics tools to be developed will be of limited utility for nutrition scientists and
clinicians if nutrition science does not play a substantial role in driving their creation. As a
start, nutrition scientists need to give engineers and software writers a list of the highest-priority
metabolites—those that we think will be most useful to nutrition science.
Nutrition experts need to contribute to the science but also to the training of health
professionals, so as to provide them with the skill sets essential for using nutrigenomic and
metabolomic data sets. The clinical nutrition specialist will need training in nutrigenomics and
metabolomics. The intricacies of the biotechnology involved in measurements may concern
only research scientists, and the catalog of important gene and metabolite changes will be
growing too fast for clinicians to be expected to master all of the content. However, there is a
critical thinking process that weights information according to the known weaknesses and
strengths of the methods used to obtain the information and then places it into a metabolic
context. The clinician will have to be trained to weigh metabolomic and nutrigenomic evidence
and convert it into recommendations. To do this, an understanding of metabolism that is
perhaps more extensive than that which current training provides will be needed. Finally,
clinical nutrition must develop the clinical infrastructure needed to efficiently perform
nutrigenomic and metabolomic profiling. It may be sufficient to perform SNP and epigenetic
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profiling once in a lifetime, but metabolomic measures would be made acutely at the time of
evaluation, and it is likely that multiple measures made before and after an intervention will
be used to assess metabolite flux. Investments made today in research methods and in training
programs can ensure a new foundation for clinical nutrition and public health practice in the
future.
It is not certain that nutrition clinicians will occupy this important clinical niche, because
geneticists, chemists, engineers, and pharmacologists currently dominate the development of
portions of nutrigenomics and metabolomics. However, before these new technologies can
effectively penetrate into clinical practice, the information generated by these methods must
be overlaid onto the integrated metabolic pathways matrix that health professionals already
understand. The depth of understanding of human metabolism that nutrition scientists have is
a critical asset needed to advance this area of study. This asset could be used to solidify a place
for nutrition clinicians in the future of nutrigenomics and metabolomics.
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DNA methylation can silence gene expression. Methylation of cytosine located in cytosine-
guanosine groupings in gene promoter regions (called 5′-CpG-3′ islands) attracts capping
proteins that hinder access to the gene for the transcription factors that normally turn on gene
expression and formation of messenger RNA (mRNA). When the transcription factor does not
bind to the promoter area of the gene, transcription of mRNA does not occur, and the gene is
silenced.
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A theoretical example of what the informatics tools may look like that will make nutrigenomics
and metabolomics accessible to nutrition scientists and clinicians. After appropriate statistical
tests and filtering, data from nutrigenomic, epigenetic, and metabolomic platforms can be
overlaid on the metabolic map that we are familiar with. By selecting an area of the metabolic
map, the user can zoom in on the region and see a presentation of changes in metabolite
concentrations, enzyme activities, and perhaps flux rates with color coding to indicate direction
of change. Information on changes in DNA expression (E), gene methylation (M), and gene
SNPs also can be presented by using similar color coding. By selecting the metabolite, enzyme,
or gene box, an investigator would be able to examine the exact values and variances and
perhaps even to examine the raw data. Another level of the informatics program would
summarize all of the related changes by pathway and present information on false discovery
and significant difference statistics. Finally, a summary of appropriate diet recommendations
would be presented.
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